Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.
about
Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcomaMalignant vascular tumors--an update.MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of primary pulmonary angiosarcomas.MicroRNA-214 Promotes Apoptosis in Canine Hemangiosarcoma by Targeting the COP1-p53 Axis.Enrichment of the embryonic stem cell reprogramming factors Oct4, Nanog, Myc, and Sox2 in benign and malignant vascular tumors.Incidences of Primary Soft Tissue Sarcoma Diagnosed on Extremities and Trunk Wall: A Population-Based Study in TaiwanRecurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcomaPrognostic implications of PIK3CA amplification in curatively resected liposarcomaHigh-risk features in radiation-associated breast angiosarcomas.Angiosarcoma of the thyroid: a case report with review of the literature.Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression.Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives.Actionable mutations in canine hemangiosarcoma.Biallelic Dicer1 Loss Mediated by aP2-Cre Drives Angiosarcoma.Searching for aurora in the night of sarcoma phase II trials: isn't it time to move to second gear?Mouse genetic background influences whether HrasG12V expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma.Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma.Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma.A review of soft-tissue sarcomas: translation of biological advances into treatment measures.Endothelial cell malignancies: new insights from the laboratory and clinic.Primary angiosarcoma of the breast-series of 11 consecutive cases-a single-centre experience.Primary Epithelioid Angiosarcoma of the Thyroid in a Patient Occupationally Exposed to RadiationsPrimary angiosarcoma arising in an angiomyolipoma of the kidney: case report and literature review
P2860
Q33919862-BC4AC534-9E55-4BF2-A9F9-4C907F825BC5Q34658662-2480887C-294D-4448-8657-1C46598C7A99Q35096201-C91EBAD5-881F-41C4-B0AD-8D1B7810F831Q35233062-BDAC5D05-429A-4F79-9E87-1331E4072D10Q35763621-DC567B88-1D67-483B-9C41-E566B902129DQ35790043-7647F257-DC38-437F-B40A-23395157AA88Q36195676-078F5548-065B-4B4D-A4CC-A54F509999DBQ36803294-B1795C47-7A8B-454C-BBFF-155483E32D65Q37161161-DDEF6CA0-83B0-41CD-990A-F912F63909DCQ37269360-665ADDBD-464D-4E21-8180-E9D53AAFED2AQ37279264-B30483FB-ACC8-4556-8A44-BBCFA2AA07D1Q38116466-E54884B3-A704-493A-8CCA-3B52E7C9B99DQ38717560-E398BE82-7B85-43FB-8DEC-7F3F508D5594Q39014708-C28242A6-BAD8-451F-9FED-3C3ED679266EQ39111280-778C6B11-00E5-495C-8DBF-C125838117E0Q42029702-C9DEE7D2-8601-4D16-9103-D991E6FFE18BQ44409594-A83A01AD-3655-4AC1-8AFA-02C888835A91Q47162757-C16640E9-60AE-44FE-8B06-EE6FC14D9E1FQ47793645-090E7FAB-287B-4EC7-A125-58C11166E1EEQ53041284-B3DC1074-80E7-405E-A1B6-295AC97D547CQ54983697-9B557C8A-AEBE-448D-8FC2-89CF1D0CC1A2Q55192373-3D77F322-D8D3-498A-9D96-2A886ED5A481Q55262749-8E01AEC4-0021-478A-8F92-8295852F8832Q55265062-063063D9-F047-4E89-9086-1DB01447AE63Q55332047-19883116-4041-4C8E-9C6F-BF210D44ACB6Q55417370-0F0CE190-3976-4F3B-A0D4-F4EE4467DEECQ57486450-D1D35996-5CD6-4444-88F1-D2D5038EAD04Q58775480-8918C41E-9ED9-4940-9C42-300B3DBD1607
P2860
Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Alterations of the p53 and PIK ...... arcomas with complex genomics.
@ast
Alterations of the p53 and PIK ...... arcomas with complex genomics.
@en
type
label
Alterations of the p53 and PIK ...... arcomas with complex genomics.
@ast
Alterations of the p53 and PIK ...... arcomas with complex genomics.
@en
prefLabel
Alterations of the p53 and PIK ...... arcomas with complex genomics.
@ast
Alterations of the p53 and PIK ...... arcomas with complex genomics.
@en
P2093
P2860
P50
P356
P1433
P1476
Alterations of the p53 and PIK ...... sarcomas with complex genomics
@en
P2093
Antoine Italiano
Chun-Liang Chen
Cristina R Antonescu
Françoise Bonnet
Jean-Michel Coindre
Michel Longy
Nicolas Sevenet
P2860
P304
P356
10.1002/CNCR.27614
P407
P577
2012-05-30T00:00:00Z